AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
rifapentine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, rifamycin derivatives | 2378 | 61379-65-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Rifapentine, a cyclopentyl rifamycin, inhibits DNA-dependent RNA polymerase in susceptible strains of Mycobacterium tuberculosis but does not affect mammalian cells at concentrations that are active against these bacteria. At therapeutic levels, rifapentine inhibits RNA transcription by preventing the initiation of RNA chain formation. It forms a stable complex with bacterial DNA-dependent RNA polymerase, leading to repression of RNA synthesis and cell death. Rifapentine and its 25-desacetyl metabolite accumulate in human monocyte-derived macrophages and are bactericidal to both intracellular and extracellular M. tuberculosis bacilli.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.11 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.367 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 8.337 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 12.162 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 6.902 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 6.640 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 15.910 | % | High | 1 |
| herg | hERG pIC50 | 4.587 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.467 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 7.295 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 8.920 | % | High | 1 |
| kinase-safety-class | ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 40 | |||
| kinase-selectivity-class | AXL,CDK4,EIF2AK3,GRK2,MAP2K6 | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 5.445 | High | 0.87 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 12.359 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 6.934 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 4.920 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 41.400 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.66 | |
| pppb | Pig plasma protein binding (% unbound) | 9.780 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.020 | % | High | 0.87 |
| rh-clint | Rat hepatocyte intrinsic clearance | 4.797 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 35.200 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 9.800 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 510.505 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 22, 1998 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Influenza like illness | 41.16 | 37.58 | 15 | 401 | 80596 | 90547435 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pyrexia | 64.12 | 40.56 | 53 | 781 | 898212 | 109690253 |
| Influenza like illness | 42.17 | 40.56 | 18 | 816 | 88394 | 110500071 |
| Product prescribing issue | 41.29 | 40.56 | 11 | 823 | 12761 | 110575704 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J04AB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics |
| FDA CS | M0019113 | Rifamycins |
| FDA EPC | N0000175501 | Rifamycin Antimycobacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000904 | Antibiotics, Antitubercular |
| MeSH PA | D000995 | Antitubercular Agents |
| MeSH PA | D007917 | Leprostatic Agents |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:35816 | leprostatic drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
Related Drugs by ATC class:
J04AB Antibiotics 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Alcoholism | contraindication | 7200002 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.06 | acidic |
| pKa2 | 7.26 | acidic |
| pKa3 | 11.03 | acidic |
| pKa4 | 11.77 | acidic |
| pKa5 | 12.55 | acidic |
| pKa6 | 7.87 | Basic |
| pKa7 | 2.32 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial DNA-directed RNA polymerase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021127 | VUID |
| N0000148581 | NUI |
| D00879 | KEGG_DRUG |
| 4021127 | VANDF |
| C0073372 | UMLSCUI |
| CHEBI:45304 | CHEBI |
| RPT | PDB_CHEM_ID |
| CHEMBL1660 | ChEMBL_ID |
| DB01201 | DRUGBANK_ID |
| C018421 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12014 | IUPHAR_LIGAND_ID |
| 4765 | INN_ID |
| XJM390A33U | UNII |
| 135403821 | PUBCHEM_CID |
| 35617 | RXNORM |
| 7483 | MMSL |
| d04327 | MMSL |
| 007675 | NDDF |
| 108686006 | SNOMEDCT_US |
| 410831004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0088-2102 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 30 sections |
| Rifapentine | Human Prescription Drug Label | 1 | 33342-599 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 27 sections |
| Priftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-1718 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 28 sections |